G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
Total abortion bans effective by early 2023 were associated with a 1.57% monthly birth-rate increase, approximately 1,210 additional births per month and ~14,500 additional births across 13 states in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results